Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26706272 | 0.92 | MEN1 (0.67) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL5726222 | 0.88 | MEN1 (0.63) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL26706687 | 0.87 | POLB (0.54) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL1647766 | 0.83 | KMT2A (0.56) | MEN1KMT2ASIRT6MAPTPOLB | |
| SCHEMBL520686 | 0.82 | SIRT6 (0.68) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL29986826 | 0.82 | SIRT6 (0.64) | MEN1KMT2ASIRT6MAPTPOLB | |
| SCHEMBL6714560 | 0.80 | MEN1 (0.73) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL29986317 | 0.79 | SIRT6 (0.59) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL16848710 | 0.79 | POLB (0.55) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL520304 | 0.78 | LMNA (0.60) | MEN1KMT2ASIRT6MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339874-A1 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339874-A1 | PIPERAZINYL COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS | EPX, EGLN3, NISCH | MEN1 4369/4885KMT2A 2620/4885SIRT6 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.